These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15770410)

  • 1. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C.
    Yoshiji H; Noguchi R; Fukui H
    J Gastroenterol; 2005 Feb; 40(2):215-6. PubMed ID: 15770410
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C.
    Yoshiji H; Noguchi R; Kojima H; Ikenaka Y; Kitade M; Kaji K; Uemura M; Yamao J; Fujimoto M; Yamazaki M; Toyohara M; Mitoro A; Fukui H
    World J Gastroenterol; 2006 Nov; 12(42):6786-91. PubMed ID: 17106926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic hepatitis C in children is a mild and curable liver disease.
    Di Marco V
    Dig Liver Dis; 2011 Apr; 43(4):266-7. PubMed ID: 21353653
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Tsujinoue H; Fukui H
    Liver Int; 2005 Feb; 25(1):153-61. PubMed ID: 15698413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
    Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic hepatitis C with normal level of alanine-aminotransferase].
    Rossi G
    Recenti Prog Med; 2004 Nov; 95(11):509-11. PubMed ID: 15598087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy.
    Nguyen HV; Mollison LC; Taylor TW; Chubb SA; Yeap BB
    Intern Med J; 2006 Jun; 36(6):362-6. PubMed ID: 16732861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR; Attia M; Badran HM; El-Tawil A; Zalata K; Barakat E; Selim O; El-Nakeeb A; Saied A
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
    Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
    Kurosaki M; Matsunaga K; Hirayama I; Tanaka T; Sato M; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Asahina Y; Miyake S; Enomoto N; Izumi N
    J Hepatol; 2008 May; 48(5):736-42. PubMed ID: 18329125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.
    Muir AJ; Sylvestre PB; Rockey DC
    J Viral Hepat; 2006 May; 13(5):322-8. PubMed ID: 16637863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
    Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
    Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.